In a recent sub-analysis, lenvatinib was shown to improve both progression-free and overall survival in older patients with radioiodine-refractory thyroid cancer.
Results from a nationwide clinical trial, which were presented at the 2017 ASCO Annual Meeting, indicate that adding pembrolizumab to standard therapy before surgery offers the potential for improving outcomes in this patient population.
Lenalidomide plus rituximab induction therapy followed by maintenance appears to provide favorable activity and a tolerable safety profile in follicular lymphoma patients who are double-refractory or had early relapse after initial diagnosis.
Anti-CD19 CAR T-cell therapy may benefit patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed or are refractory to standard therapy.
CAR T-cell therapy may have a role in combating relapsed/refractory multiple myeloma, according to new data from a phase I study presented at the 2017 ASCO Annual Meeting, held June 2–6 in Chicago.
Brentuximab vedotin, a monoclonal antibody-drug conjugate, combined with gemcitabine may be a new treatment option for children and AYAs with relapsed or refractory Hodgkin lymphoma.
A two-pronged algorithm, which includes an analysis for a gene signature and tumor mutational burden, may be a potential new tool for predicting treatment response to checkpoint inhibitors.
A new triple therapy approach using a checkpoint inhibitor and T-cell therapy is showing considerable promise in the treatment of Merkel cell carcinoma.
Atezolizumab was approved for treating patients with metastatic non–small-cell lung cancer who experienced disease progression during or following platinum-containing chemotherapy. Now, it turns out this agent may have a role in combating breast cancer.
A new study has found that high tumor mutation load is associated with older age, absence of oncogenic mutations, and presence of tumor suppressor gene mutations.